Allergan, Inc. v. Apotex Inc., No. 13-1245 (Fed. Cir. June 10, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Apotex Inc., Apotex Corp., Sandoz, Inc., Hit -Tech Pharmacal Co., Inc., Actavis, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc. (collectively “appellants”) appeal from a final judgment of the U.S. District Court for the Middle District of North Carolina finding that appe l- lants had infringed claims of U.S. Patent Nos. 7,388,029 (“’029 patent”) and 7,351,404 (“’404 patent”) and had failed to establish they were invalid. F or the reasons stated below, we reverse the district court’s findings with respect to the validity of each patent.